INT87343

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2000
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 34
Total Number 35
Disease Relevance 18.38
Pain Relevance 1.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular matrix organization (PTK2) embryo development (PTK2) microtubule organizing center (PTK2)
cytoplasm (PTK2) signal transducer activity (PTK2) cytosol (PTK2)
Anatomy Link Frequency
AsPC-1 10
MCF7 2
PTK2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Opioid 8 99.82 Very High Very High Very High
cINOD 4 85.76 High High
metalloproteinase 28 71.44 Quite High
MU agonist 1 68.52 Quite High
opioid receptor 1 66.68 Quite High
opiate 1 62.88 Quite High
palliative 31 8.72 Low Low
cytokine 2 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
chemokine 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pancreatic Cancer 1502 99.30 Very High Very High Very High
Adhesions 296 99.26 Very High Very High Very High
Cancer 732 99.16 Very High Very High Very High
Apoptosis 1192 99.12 Very High Very High Very High
Skin Cancer 8 97.28 Very High Very High Very High
Malignant Neoplastic Disease 70 97.06 Very High Very High Very High
Breast Cancer 75 96.76 Very High Very High Very High
Colon Cancer 18 92.28 High High
Reprotox - General 1 116 91.60 High High
Reprotox - General 3 4 89.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These drugs also reduced the tyrosine phosphorylation of FAK and an associated factor, p130Cas.
Negative_regulation (reduced) of Phosphorylation (phosphorylation) of FAK
1) Confidence 0.59 Published 2000 Journal Clin. Cancer Res. Section Abstract Doc Link 10741720 Disease Relevance 0.87 Pain Relevance 0.27
The C-terminal non-catalytic domain of FAK termed FRNK functions as a competitive inhibitor of FAK and ectopic expression of FRNK specifically inhibits FAK autophosphorylation at Tyr397 and thus attenuates its activity [19,20].
Negative_regulation (inhibits) of Phosphorylation (autophosphorylation) of FAK
2) Confidence 0.56 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.65 Pain Relevance 0
We used PF-228 to downregulate constitutive FAK phosphorylation in Panc-1 cells and LN-induced FAK phosphorylation in Aspc-1 cells respectively.
Negative_regulation (downregulate) of Phosphorylation (phosphorylation) of FAK
3) Confidence 0.56 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.38 Pain Relevance 0
It specifically blocks FAK phosphorylation and thus targets FAK catalytic activity.
Negative_regulation (blocks) of Phosphorylation (phosphorylation) of FAK
4) Confidence 0.56 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.41 Pain Relevance 0
These results clearly showed that, inhibition of constitutive FAK phosphorylation was sufficient to render Panc-1 cells more chemosensitive to Gem.
Negative_regulation (inhibition) of Phosphorylation (phosphorylation) of FAK
5) Confidence 0.56 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.44 Pain Relevance 0
Our research showed that specific inhibition of constitutive FAK phosphorylation decreased Akt but not ERK phosphorylation in Panc-1 cells.
Negative_regulation (inhibition) of Phosphorylation (phosphorylation) of FAK
6) Confidence 0.56 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.23 Pain Relevance 0
Therefore, a commercially available and more specific inhibitor of FAK phosphorylation, PF-228, was chosen in our study.
Negative_regulation (inhibitor) of Phosphorylation (phosphorylation) of FAK
7) Confidence 0.56 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.63 Pain Relevance 0
It further confirms the role of constitutive FAK phosphorylation in the intrinsic chemoresistance to Gem in pancreatic cancer cells and indicates development of selective FAK phosphorylation inhibitors may be a promising way to enhance chemosensitivity in pancreatic cancer.
Negative_regulation (inhibitors) of Phosphorylation (phosphorylation) of FAK associated with pancreatic cancer
8) Confidence 0.56 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.91 Pain Relevance 0
PF-228 is a more specific method to decrease FAK phosphorylation compared with FRNK overexpression.
Negative_regulation (decrease) of Phosphorylation (phosphorylation) of FAK
9) Confidence 0.56 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.40 Pain Relevance 0
We used two different kinds of plasmids to downregulate FAK phosphorylation in Panc-1 cells, which had higher constitutive pFAK (pY397) level.
Negative_regulation (downregulate) of Phosphorylation (phosphorylation) of FAK
10) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.14 Pain Relevance 0
Recently, a novel small molecule inhibitor, PF-573,228 (here after referred to as PF-228), has been developed to block FAK phosphorylation on Tyr397 and target FAK catalytic activity, which provides an appropriate tool to dissect the role of FAK phosphorylation [22].
Negative_regulation (block) of Phosphorylation (phosphorylation) of FAK
11) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.78 Pain Relevance 0
Development of selective FAK phosphorylation inhibitors may be a promising way to enhance chemosensitivity in pancreatic cancer.



Negative_regulation (inhibitors) of Phosphorylation (phosphorylation) of FAK associated with pancreatic cancer
12) Confidence 0.41 Published 2009 Journal Mol Cancer Section Abstract Doc Link PMC2806309 Disease Relevance 0.45 Pain Relevance 0
Moreover, inhibition of constitutive FAK phosphorylation in Panc-1 cells and LN-induced FAK phosphorylation in AsPC-1 cells by a novel and more specific FAK phosphorylation inhibitor PF-573,228 showed similar results with those of FAK phosphorylation inhibition by FAK RNAi or FRNK overexpression.


Negative_regulation (inhibition) of Phosphorylation (phosphorylation) of FAK in AsPC-1
13) Confidence 0.41 Published 2009 Journal Mol Cancer Section Abstract Doc Link PMC2806309 Disease Relevance 0.58 Pain Relevance 0
Small molecule inhibitors of FAK phosphorylation (such as PF-573,228, PF-562,271, TAE226, 1,2,4,5-Benzenetetraamine tetrahydrochloride) have been developed in recent years [22,38-40].
Negative_regulation (inhibitors) of Phosphorylation (phosphorylation) of FAK
14) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.57 Pain Relevance 0
As expected, transient transfection experiments showed that both methodological approaches could inhibit FAK phosphorylation in Panc-1 cells.
Negative_regulation (inhibit) of Phosphorylation (phosphorylation) of FAK
15) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.09 Pain Relevance 0
However, FAK related non-kinase (FRNK) can compete with FAK for focal adhesion binding sites and thus specifically inhibit FAK phosphorylation and downstream signaling without changing expression [19-21].
Negative_regulation (inhibit) of Phosphorylation (phosphorylation) of FAK associated with adhesions
16) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 1.01 Pain Relevance 0
Moreover, inhibition of constitutive FAK phosphorylation in Panc-1 cells and LN-induced FAK phosphorylation in AsPC-1 cells by a novel and more specific FAK phosphorylation inhibitor PF-573,228 showed similar results with those of FAK phosphorylation inhibition by FAK RNAi or FRNK overexpression.


Negative_regulation (inhibition) of Phosphorylation (phosphorylation) of FAK in AsPC-1
17) Confidence 0.41 Published 2009 Journal Mol Cancer Section Abstract Doc Link PMC2806309 Disease Relevance 0.45 Pain Relevance 0
Compared with FRNK overexpression, PF-228 is a more specific method to decrease FAK phosphorylation.
Negative_regulation (decrease) of Phosphorylation (phosphorylation) of FAK
18) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.56 Pain Relevance 0
We used PF-228 to downregulate constitutive FAK phosphorylation in Panc-1 cells and LN-induced FAK phosphorylation in Aspc-1 cells respectively.
Negative_regulation (downregulate) of Phosphorylation (phosphorylation) of FAK
19) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.38 Pain Relevance 0
Moreover, inhibition of FAK phosphorylation by FRNK overexpression antagonized the effects of LN on survivin expression and Bad phosphorylation at Ser136 in AsPC-1 cells (Fig. 10D).
Negative_regulation (inhibition) of Phosphorylation (phosphorylation) of FAK in AsPC-1
20) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.45 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox